Compare James Hardie Industries plc. Ordinary Shares (JHX) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
James Hardie Industries plc. Ordinary Shares vs Sana Biotechnology Inc — how do they compare? James Hardie Industries plc. Ordinary Shares trades at $25.12 (market cap $14.60B), while Sana Biotechnology Inc trades at $2.79 (market cap $836.71M). The key difference: James Hardie Industries plc. Ordinary Shares is far larger — about 17.4× Sana Biotechnology Inc's market cap, and James Hardie Industries plc. Ordinary Shares is trading nearer its 52-week high, Sana Biotechnology Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold James Hardie Industries plc. Ordinary Shares for 1 Days and Sana Biotechnology Inc for 23 Days on average.
| JHX | SANA | |
|---|---|---|
Market Cap | $14.60B | $836.71M |
Volume | 7,262,924 | 4,507,444 |
Sector | Basic Materials | Health |
52-Week High | $31.08 | $5.92 |
52-Week Low | $16.69 | $2.68 |
Typical Hold Time | 1 Days | 23 Days |
Enterprise Value | $18.83B | $749.96M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
SANA Biotechnology trades at $2.79, up 2.57% today, but faces significant fundamental challenges with negative revenue, substantial losses, and bearish technical indicators. The company reported a net loss of $244.17 million in 2025 with no revenue, while technical analysis shows a bearish trend with moving averages and ADX indicators signaling selling pressure. Recent news highlights multiple investor conference presentations and ongoing legal scrutiny regarding fiduciary duties.
Despite strong analyst support (82% buy ratings), SANA's lack of revenue generation and negative profitability metrics present substantial investment risk. The company's cash flow remains negative, requiring continued financing. Near-term catalysts include upcoming Q3 earnings and clinical developments, but investors should weigh the high-risk profile against potential long-term biotechnology breakthroughs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About James Hardie Industries plc. Ordinary Shares
James Hardie manufactures fiber cement products for residential and commercial construction. Its portfolio includes exterior siding, interior boards, and other building materials.
Read more on JHX →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
